The cannabinoid CB1 receptor (CB1) is one of the most abundant G protein-coupled receptors in the brain, but little is known about the mechanisms that modulate CB1 receptor signaling. Here, we show that inhibition or null mutation of the epsilon isozyme of protein kinase C (PKCe) selectively enhances behavioral responses to the CB1 agonist WIN55,212-2 in mice, but not to the structurally unrelated CB1 agonist CP55,940. 
INTRODUCTION
The cannabinoid CB1 receptor (CB1) is a GPCR that is widely expressed in the central nervous system (Herkenham, 1991) . In addition to mediating marijuana's psychoactive effects, CB1 receptors respond to the endogenous endocannabinoids arachidonylethanolamine (anandamide, AEA) and 2-arachidonylglycerol to regulate neuronal excitability and neurotransmitter release. CB1 receptors are coupled to G i/o heterotrimeric G proteins and their activation leads to the inhibition of adenylyl cyclase, activation of extracellular signal-regulated kinases 1 and 2, increased function of G protein-activated, inwardly rectifying K + (GIRK) channels and inhibition of voltage-gated calcium channels (Howlett et al, 2004) . The receptor is highly expressed in the cerebral cortex, hippocampus, striatum, cerebellum and reward centers of the limbic system (Herkenham, 1991) . As a consequence, CB1 receptors play an important role in a variety of behavioral states including pain, learning and memory, drug reward, and feeding Gardner and Vorel, 1998; Harkany et al, 2007; Kreitzer et al, 2002) .
Although much is known about downstream-signaling cascades regulated by CB1 receptor activation, there is very little information about signaling cascades that regulate CB1 receptor sensitivity to ligands. One study suggests that CB1 receptor function is regulated by protein kinase C (PKC) (Garcia et al, 1998) , which is a family of phospholipiddependent, serine-threonine kinases encoded by nine different genes (Olive and Messing, 2004) . In anterior pituitary At-T20 cells treated with the CB1 agonist R-( + )- [2, pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone mesylate (WIN55,212-2), activation of PKC with phorbol 12-myristate, 13-acetate attenuates CB1-mediated suppression of P/Q type calcium currents and activation of GIRK currents (Garcia et al, 1998) . In vitro, a mixture of PKC isozymes purified from rat brain phosphorylates CB1 at Ser 317 in the third intracellular loop. Mutation of this serine residue to alanine prevents phorbol ester-mediated disruption of CB1 signaling, suggesting that PKC phosphorylates and negatively regulates CB1 signaling through phosphorylation of CB1 at Ser 317 (Garcia et al, 1998) . It is not known if PKC similarly regulates the effects of WIN55,212-2 on neuronal CB1 receptors and, if so, which PKC isozymes are involved.
Seven PKC isozymes (a, b, g, d, e, Z, and y) can be activated by tumor-promoting phorbol esters, which are widely used probes of PKC function. We chose to study the epsilon isozyme of PKC because mice that lack this enzyme show enhanced behavioral responses to ethanol (Hodge et al, 1999) and morphine (Newton et al, 2007) . The endogenous cannabinoid system regulates ethanol intake in rodents (Hansson et al, 2007; Hungund et al, 2002) and cannabinoid and opioid receptor systems have been shown to interact (Caille et al, 2007; Caille and Parsons, 2006; Vigano et al, 2005) . In addition, both CB1 and PKCe are abundantly expressed throughout the nervous system (Choi et al, 2002; Garcia-Navarro et al, 1994) , especially in presynaptic terminals (Saito et al, 1993) . We found that inhibition or deletion of PKCe selectively increased behavioral sensitivity to the CB1 agonist WIN55,212-2 but not 2-[(1S,2R,5S)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol (CP55,940). We also found that brain membranes from PKCe À/À mice showed increased binding affinity for WIN55,212 but not for 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide (SR141716A). Behavioral tolerance to WIN55,212-2 was also increased in PKCe À/À mice compared with PKCe + / + mice. Together, our findings suggest that PKCe negatively regulates the actions of WIN55,212-2 at the CB1 receptor.
MATERIALS AND METHODS

Animals
PKCe À/À mice (Khasar et al, 1999) were maintained on inbred 129S4/SvJae and C57BL6/J backgrounds and crossed to generate PKCe + /À C57BL/6JX129S4/SvJae F1 hybrid mice. These mice were intercrossed to generate F2 hybrid PKCe + / + and PKCe À/À littermates for experiments. We used 8-to 16-week-old male mice for all studies. Mice were housed under a 12 : 12 h light-dark cycle in groups of five per cage with food and water ad libitum. All procedures were conducted in accordance with NIH and Gallo Center Institutional Animal Care and Use Committee guidelines. Cannabinoid-induced analgesia and hypothermia were measured concurrently on the same animals; other studies were performed using drug-naive mice. EC 50 values were calculated from sigmoid dose-response curves using Prism 4.0 (GraphPad Software, San Diego, CA, USA).
Reagents
WIN55,212-2 and CP55,940 were purchased from SigmaAldrich (St Louis, MO, USA) and were dissolved in 0.9% saline containing 0.1% Tween 80. The peptides Tat-eV1-2 (YGRKKRRQRRRC-CEAVSLKPT) and Tat-scrambled-eV1-2 (YGRKKRRQRRRC-CLSETKPAV) were synthesized by Anaspec (San Jose, CA, USA). 
Analgesia
We measured analgesia by the tail-flick test (Reggio et al, 1991) , using a beam of light focused on the underside of the tail as the nociceptive stimulus (Columbia Instruments, Columbus, OH, USA). Mean baseline tail-flick response time was calculated from three consecutive stimulations along the length of the tail. We used a maximal stimulation time of 10 s. One PKCe À/À mouse did not flick its tail within this time period and was eliminated from this study. For each mouse, we measured baseline tail-flick latency and then tail-flick latency following treatment with WIN55,212-2 or CP55,940. Peak analgesia occurred 1 h after s.c. administration of drug; therefore, we tested drug responses 1 h after administration. To confirm that WIN55,212-2 responses were mediated by CB1 receptors, we pretreated some mice with SR141716A (3 mg/kg) 15 min prior to administering WIN55,212-2. Analgesia was calculated as the percent of maximal possible effect: (%MPE ¼ [(test latency-baseline latency)/(10-baseline latency] Â 100).
Hypothermia
We measured hypothermia immediately following analgesia by inserting a thermocouple thermometer (Type J, Barnant Co., Barrington, IL, USA) 2 cm into the mouse's rectum. Hypothermia was calculated as the change in core body temperature from baseline (Adams and Martin, 1996) .
Locomotor Activity
Locomotor activity was monitored using 46 Â 46 cm open field chambers (Med Associates, St Albans, VT, USA) in dark, sound attenuating boxes. Mice received an injection of vehicle or WIN55,212-2 and were immediately placed in the test chamber. Their distance traveled was recorded for 1 h.
Analgesia and Hypothermia following Repeated WIN55,212-2 Treatment
On day 1, mice were tested for acute sensitivity to WIN55,212-2-induced analgesia and hypothermia, as described above. On days 2-7, they received two daily s.c. injections (at 0900 and 1700 h) of equipotent doses (ED 75 ) of WIN55,212-2 (0.9 mg/kg for PKCe À/À and 2.5 mg/kg for PKCe + / + mice), as determined from the acute doseresponse curve for each genotype. This dose was chosen based on prior studies of cannabinoid tolerance (Cook et al, 1998; Sim-Selley and Martin, 2002) . On day 8, mice were retested for WIN55,212-2-induced analgesia and hypothermia using the same doses (0.5-4.0 mg/kg) used on day 1. The magnitude of tolerance to analgesia was calculated by subtracting the mean % MPE on day 8 from the mean % MPE on day 1. The magnitude of tolerance to hypothermia was calculated by subtracting the core body temperature on day 8 from the core body temperature on day 1.
Analgesia following Intracerebroventricular Microinjection of Tat-eV1-2
PKCe + / + mice were anesthetized with ketamine 100 mg/kg i.p. and xylazine 10 mg/kg i.p. A mouse stereotaxic tracking device (RBM-IT Anilam, Painesville, OH, USA) and stereotaxic table (Kopf, Tujunga, CA, USA) were used to implant 26-G guide cannulae into the right and left ventricles (coordinates relative to bregma: anteroposterior, 0; mediolateral, ± 1.1; dorsoventral, 3.0 (Franklin and Paxinos, 1992) ). Cannulae were stabilized with acrylic dental cement (Lang Dental Manufacturing, Wheeling, IL, USA), and dummy cannulae and dust caps were put in place (Plastics One, Wallingford, CT, USA). Ten days later, TateV1-2 or Tat-scrambled-eV1-2 (20 mM each) were infused bilaterally using 3 mm, 26-G cannulae (Plastics One, Wallingford, CT, USA) attached to 1 ml syringes (Hamilton, Reno, NV, USA) and a PHD 2000 pump (Harvard Apparatus, Holliston, MA, USA). The injection volume was 1 ml with a flow rate of 1 ml/10 min. Thirty minutes after infusion, mice were injected with 1 mg/kg WIN55,212-2 or vehicle s.c. and tested 1 h later for tail-flick analgesia and hypothermia. Cannulae placement was verified by histological analysis of brain sections. 3 H]WIN55,212-2 saturation binding was performed as described (Nakazi et al, 2000) . The maximal binding capacity (Bmax) and the dissociation constant (Kd) were calculated by nonlinear curve fitting using Prism 4.0 (GraphPad Software, San Diego, CA, USA).
Radioligand Binding to Whole Brain Membranes
[ 3 H] SR141716A saturation binding was measured as described (Breivogel et al, 2001) except that the amount of protein per tube was 100 mg and 2.5 mM of the CB1 inverse agonist/ antagonist AM 251 (Tocris Cookson, Bristol, UK) was used to measure non-specific binding. Competitive [ 3 H] WIN55,212-2 binding was measured in a manner similar to saturation binding except that a fixed concentration of the tracer ligand was used and the competing ligand was SR141716A. The effect of the non-hydrolyzable guanine nucleotide guanylylimidodiphosphate (GPP(NH)p), 100 mM) on agonist binding to the CB1 receptor was conducted in a manner similar to that described by (Lambert and Childers, 1984) except that [ 3 H]WIN55,212-2 was used as agonist and SR141716A was the competing ligand. Nonlinear curve fitting and area under the curves were analyzed using Prism 4.0 (GraphPad Software, San Diego, CA, USA).
Anti-CB1-pSer316 Immunoreactivity
Mice were killed by CO 2 inhalation and decapitation. Amygdala, hippocampus, cortex, striatum and cerebellum were immediately dissected on ice. Tissues were homogenized at 41C in modified RIPA buffer containing 50 mM Tris-HCl (pH 7.4) 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.25% sodium deoxycholate, 1 mM PMSF, Completet protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN, USA), and 1 : 100 dilution of serine/threonine phosphatase inhibitor cocktail 1 (Sigma-Aldrich, St Louis, MO, USA). The homogenates were mixed at 41C for 30 min and centrifuged at 6000 g for 5 min at 41C. Supernatants were collected and adjusted to a concentration of 2 mg/ml. The concentrated sample buffer solution contained 62.5 mM Tris-HCl (pH 6.8), 2% SDS, 5% b-mercaptoethanol, 10% glycerol and 0.002% bromophenol blue. Samples were boiled at 901C for 7 min and then passed through a 27-G needle. Equal amounts of protein (40 mg/lane) were loaded onto duplicate 4-12% Tris-bis glycine SDS-polyacrylamide gels. The separated proteins were transferred to nitrocellulose membranes (Hybondt-C Extra, Amersham Biosciences, Buckinghamshire, England), then blocked for 1 h at 251C with either 5% BSA in 0.01 M TBS containing 0.1% Tween 20 for the anti-phospho-CB1 antibody or with 5% nonfat dry milk in 1 Â PBS containing 0.1% Tween 20 for the anti-CB1 antibody. Each pair of membranes was then incubated with anti-phospho-CB1 (Ser 316) antibody (1 : 500 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or with anti-CB1 antibody (1 : 500 dilution; Santa Cruz Biotechnology) overnight at 41C. Specificity of the anti-phospho-CB1 (Ser 316) antibody for the phosphorylated form of CB1 in mouse brain has been demonstrated by the manufacturer (Santa Cruz Biotechnology catalog no. sc-17555). Membranes incubated with anti-CB1 were also incubated with anti-actin (clone AC40 at 1 : 2000 dilution; Sigma-Aldrich) or anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (1 : 2500 dilution; Abcam, Cambridge, MA, USA) to control for protein loading. Membranes were washed 1 Â TBS or PBS containing 0.1% Tween 20, three times for 5 min, then incubated with peroxidase-conjugated goat anti-rabbit IgG (1 : 1000 dilution; Roche Applied Science). Immunoreactivity was visualized by enhanced chemiluminescence (Pierce, Rockford, IL, USA).
Immunoreactive bands were detected using X-ray film and the optical density of each band was quantified using a flat bed scanner and the program Image J (http:// rsb.info.nih.gov/ij). Values for CB1 immunoreactivity were normalized to GAPDH immunoreactivity in the same sample. Values for phospho-CB1 were measured relative to total CB1 immunoreactivity in the same sample. The results for each brain area were analyzed using unpaired, two-tailed t-tests.
RESULTS
PKCe
À/À Mice show Increased Behavioral Sensitivity to WIN55,212-2 CB1 agonists produce hypothermia, analgesia, and hypolocomotion in rodents (Adams and Martin, 1996) . We measured these responses to determine if the effects of WIN55,212-2 differ between PKCe + / + and PKCe À/À mice. In agreement with previous studies, we found that there were no baseline differences in analgesia (Newton et al, 2007) , locomotor behavior (Hodge et al, 1999) and hypothermia (Olive et al, 2000) . We found that PKCe À/À mice show greater hypothermia than PKCe + / + littermates ( Figure 1a) . A two-factor ANOVA showed an effect of genotype (F (1, 63) ¼ 41.19, po0.0001) and dose (F (3, 63) ¼ 59.63, po0.0001) with an interaction between these factors (F (3, 63) ¼ 3.331 po0.025). Nonlinear regression analysis showed that the log EC 50 values for WIN55,212-2 -induced hypothermia were nearly statistically different (po0.06) between PKCe À/À mice (À0.78 ± 6.5 mg/kg) and PKCe + / + mice (0.28±0.85 mg/kg). The maximal responses were significantly different, (po0.005), indicating greater efficacy of WIN55,212-2 for producing hypothermia in PKCe À/À mice. There were no baseline differences between the genotypes (data not shown) (Figure 1a ). To determine if the increased effect of WIN55,212-2 is CB1 receptor-mediated, we administered the CB1 receptor inverse agonist/antagonist SR141716A to PKCe À/À mice and found that it completely blocked the hypothermia produced by an ED 84 dose of WIN55,212-2 (Figure 1b) . PKCe À/À mice also showed greater tail-flick analgesia than PKCe + / + mice ( Figure 1c) . A two-factor ANOVA showed an effect of genotype (F (1.58) ¼ 9.552, po0.0031) and dose (F (3, 58) ¼ 2.66. po0.0001) with a strong trend towards an interaction between these factors (F (3, 58) ¼ 2.66, po0.056). The log EC 50 for WIN55,212-2-induced analgesia in PKCe À/À mice (À0.32±0.1 mg/kg) was significantly greater (po0.01) than the log EC 50 in PKCe + / + mice (0.0006 ± 0.09). These results indicate that WIN55,212-2 is a more potent analgesic in PKCe À/À mice than in PKCe + / + mice. As the tail-flick assay is carried out for a maximum of 10 s, it is not possible to measure efficacy. The analgesia produced by an ED 84 dose WIN55,212-2 in PKCe À/À mice was blocked by SR141716A (Figure 1d ), indicating that this response was mediated through CB1. WIN55,212-2 produced locomotor suppression that was greater in PKCe À/À mice compared with wild-type littermates (Figure 1e) (Figure 1f ) was reversed by SR141716A. These results indicate that deletion of PKCe enhances hypothermic, analgesic, and locomotor inhibitory responses to WIN55,212-2. The PKCe Inhibitor eV1-2 Increases WIN55,212-2-Induced Analgesia and Hypothermia in PKCe + / + Mice
To confirm that the increased behavioral response to WIN55,212-2 observed in PKCe À/À mice was due to the absence of PKCe and not to an effect on development, we examined whether phenotypes in PKCe À/À mice could be produced in wild-type mice by treatment with a PKCe inhibitor. For this experiment, we injected the PKCe translocation inhibitor eV1-2 bilaterally into the lateral ventricles of PKCe + / + mice and then measured their analgesic and hypothermic responses after treatment with 1 mg/kg WIN55,212-2. To facilitate transport of the peptide across cell membranes, we used eV1-2 conjugated to the sequence YGRKKRRQRRR, derived from the HIV Tat protein (Chen et al, 2001) . The specificity of this peptide inhibitor for PKCe has been described earlier (Gray et al, 1997; Johnson et al, 1996) . We found that, similar to PKCe À/À mice, wild-type mice treated with Tat-eV1-2 showed greater WIN55,212-2-induced tail-flick analgesia and hypothermia than PKCe + / + mice treated with the control peptide, Tat-scrambled-eV1-2, or Tat-eV1-2 f ollowed by vehicle instead of WIN55,212-2 (Figure 2a and b) . These findings indicate that the phenotypes we observed in PKCe À/À mice are due to absence of PKCe rather than to effects of PKCe deletion on development.
PKCe À/À Mice show Normal Sensitivity to CP55,940 In Vivo
To determine if PKCe À/À mice showed increased sensitivity to a CB1 agonist that is structurally dissimilar to WIN55,21-2 (Compton et al, 1992) , we examined CP55,940-induced hypothermia and analgesia. Unlike WIN55,212-2, CP55,940 produced a similar level of hypothermia in both genotypes (Figure 3a) . ANOVA showed no main effects of genotype (F (1, 24) Agonist binding to G-protein-coupled receptors (GPCRs) promotes receptor coupling to G proteins, which in turn increases receptor affinity for agonist (Maguire et al, 1976) . Therefore, we considered whether increased affinity of PKCe À/À brain membranes for [ 3 H]WIN55,212-2 was caused by an increase in the proportion of high affinity receptors resulting from G-protein-mediated effects on agonist affinity. The proportion of receptors in the high affinity state can be measured by conducting displacement binding experiments in the presence or absence of saturating concentrations of a GTP analog such as GPP(NH)p (Jiang et al, 2001; Maguire et al, 1976) . A high concentration (100 mM) of GPP(NH)p uncouples the G-protein-receptor complex thereby eliminating the high affinity binding state for agonist.
To determine whether the absence of PKCe produces a greater proportion of CB1 receptors that exist in a high affinity binding state for [ 3 H]WIN55,212-2, we performed GPP(NH)p shift analysis using SR141716A as the displacing Figure 2 A peptide inhibitor of PKCe increases the response to WIN55,212-2. (a) Wild-type mice pretreated with Tat-eV1-2 (ev1) showed greater tail-flick analgesia than mice pretreated with the Tatscrambled-eV1-2 peptide (scr) followed by WIN55,212-2 (1 mg/kg) or mice pretreated with Tat-eV1-2 followed by vehicle (Veh) (F (2, 130) ¼ 5.63, po0.02; *po0.05 compared with sc-WIN or ev1-Veh by Tukey test). (b) Wild-type mice pretreated with the Tat-eV1-2 peptide showed greater WIN55,212-2 (1 mg/kg)-induced hypothermia than mice pretreated with Tat-scrambled-eV1-2 followed by WIN55,212-2 (1 mg/kg) or mice pretreated with Tat-eV1-2 followed by vehicle (F (2, 130) ¼ 6.11, p ¼ 0.01; *po0.05 compared with sc-WIN or ev1-Veh by Tukey test). Data shown are mean ± SEM values from of three to seven animals per treatment.
ligand. To determine the shift, we first analyzed binding using nonlinear regression analysis with a one-site competition model. As expected from our results for saturation binding, in the absence of GPP (NH) The analysis above indicated that GPP(NH)p reduces binding in both genotypes. To determine whether the degree to which GPP(NH)p reduced binding was different between the genotypes, we measured the areas under the binding curves and compared them by ANOVA with factors for genotype and treatment with GPP(NH)p . This analysis revealed that GPP(NH)p decreased binding to a similar extent in membranes from both genotypes (Figure 5b ). There was a significant effect of genotype (F (1, 10) ¼ 14.04, po0.004) and GPP(NH)p treatment (F (1, 10) ¼ 14.04, po0.0001) and no interaction between these factors (F (1, 10) ¼ 0.43, p ¼ 0.53), These results indicate that increased affinity of [ 3 H]WIN55,212-2 for CB1 in PKCe À/À membranes is not due to an increase in the proportion of receptors that exist in a high affinity state, resulting from an enhanced effect of G-protein coupling on agonist affinity.
À/À Mice Show Increased Behavioral Tolerance to WIN55,212-2 WIN55,212-2 produces robust tolerance in vivo (Maldonado, 2002; Sim-Selley and Martin, 2002) . Our data showing that WIN55,212-2 binding and WIN55,212-2-induced behaviors are increased in PKCe À/À mice suggest that CB1 receptor signaling is increased in PKCe À/À mice. Therefore, we predicted that tolerance to WIN55,212-2 would also be increased in PKCe À/À mice. To test this hypothesis, we examined hypothermic and analgesic responses after repeated, equipotent WIN55,212-2 dosing. PKCe À/À mice developed tolerance to WIN55, 212-2-induced hypothermia after repeated treatment (Figure 6a ). Analysis of these data by two-factor ANOVA showed main effects of treatment (F (1, 68) ¼ 90.47, po0.0001) and dose (F (3, 68) ¼ 33.95, po0.0001) and a significant interaction between these factors (F (3, 68) ¼ 4.18, po0.01). Similarly, PKCe + / + mice also displayed tolerance to WIN55,212-2-induced hypothermia ( Figure 6b ) and two-way ANOVA also showed main effects of treatment (F (1, 50) ¼ 38.6, po0.0001) and dose (F (3, 50) ¼ 27.91, po0.0001), with an interaction between these factors (F (3, 50) ¼ 6.26, po0.001). Comparison of the magnitude of tolerance to hypothermia revealed that PKCe À/À mice showed increased tolerance when compared with PKCe + / + littermates (Figure 6c ). Two-way ANOVA showed main effects of genotype (F (1, 55) ¼ 4.756, po0.05) and dose (F (3, 55) ¼ 7.31, po0.001) without a significant interaction between these factors (F (3, 55) ¼ 1.43, p40.05).
PKCe À/À mice also displayed tolerance to WIN55,212-2 analgesia following repeated treatment (Figure 6d ) and twoway ANOVA showed main effects of treatment (F (1, 69) ¼ 45.88, po0.0001) and dose (F (3, 69) ¼ 23.2, po0.0001), with an interaction between these factors (F (3, 69) ¼ 3.06, po0.05). However, although there was a trend toward an effect, repeated treatment of PKCe + / + mice (Figure 6e ) did not produce statistically significant analgesic tolerance when compared with acute treatment by two-way ANOVA (F (1, 53) ¼ 3.49, po0.067). There was a main effect of dose (F (3, 53) ¼ 22.59, po0.0001) but there was no interaction between treatment and dose (F (3, 53) ¼ 0.45, p40.05). As with hypothermia, the magnitude of tolerance to WIN55,212-2-induced analgesia was greater in PKCe À/À mice when compared with PKCe + / + mice (Figure 6f) , with main effects of genotype (F (1, 63) ¼ 5.02, po0.05) and dose (F (3, 63) ¼ 2.979, po0.05) and a significant interaction between these factors (F (3, 63) ¼ 4.023, po0.01).
Ser-317 Phosphorylation is not Altered in PKCe
À/À Mice Ser 317 of rat CB1 is a locus for PKC-dependent phosphorylation of heterologously expressed CB1 receptors in At-t20 cells, and phosphorylation of this site by PKC decreases WIN55,212-2 signaling (Garcia et al, 1998) . As our results indicated that PKCe regulates effects of WIN55,212-2 at brain CB1 receptors, we evaluated cortical, amygdalar, cerebellar, hippocampal and striatal membranes for CB1-pSer317 immunoreactivity. The antibody we used was generated against an epitope containing Ser 316 of the human CB1 receptor; this residue is equivalent to Ser 317 of the rat and mouse receptor. We found that, in all brain areas examined, both the amount of total CB1 immunoreactivity (Figure 7a and b) and the percentage of anti-phospho-CB1 (Ser 317) immunoreactivity (Figure 7a and c) were similar between the genotypes (p40.05 by two-tailed, unpaired t-tests). These results suggest that PKCe regulates brain CB1 receptor signaling through phosphorylation of a site other than Ser 317 of mouse CB1.
DISCUSSION
The principle finding of this study was that mice lacking PKCe exhibit increased sensitivity to the cannabinoid agonist WIN55,212-2. Inhibition of PKCe by a selective peptide inhibitor also increased sensitivity to WIN55,212-2 in wild-type mice, confirming that the PKCe À/À phenotype is due to the absence of PKCe signaling rather than a developmental abnormality. The increase in behavioral sensitivity appeared selective for WIN55,212-2 because there was no difference between PKCe À/À and PKCe We do not yet know the mechanism by which PKCe regulates the affinity of WIN55,212-2 for CB1. The results of our GPP(NH)p shift assay suggest that PKCe does not regulate the affinity WIN55,212-2 binding by altering G-protein modulation of receptor affinity for agonist. It is noteworthy that lack of PKCe increased WIN55,212-2 binding but not SR1417116A binding, and increased WIN55,212-2 but not CP55,940 behavioral effects, indicating that PKCe regulation of CB1 is highly ligand selective. This is of interest as CB1 receptor ligands are structurally diverse and can produce different effects on CB1 signaling and trafficking, probably by binding to different sites on the receptor (Howlett, 2002; Martini et al, 2007) . Indeed, evidence from computational and mutational studies indicates the presence of multiple ligand-binding sites on CB1. For example, mutation of human CB1 at Thr 210 to alanine or isoleucine differentially alters the affinity of agonists and inverse agonists (D'Antona et al, 2006) , whereas mutation of Lys 192 to alanine alters the binding of anandamide, CP55,940, HU-210 and SR141716A, but not of WIN55,212-2 (Chin et al, 1998; Hurst et al, 2002; Song and Bonner, 1996) . In contrast, mutation of Ser 383 perturbs the helical structure of CB1 such that CP55,940 binding is eliminated but WIN55,212-2 and SR141716A binding are not (Kapur et al, 2007) . Evidence from structural modeling and site-directed mutagenesis indicates that there is a binding pocket for WIN55,212-2 within a CB1 aromatic microdomain formed by transmembrane helices 3-4-5-6 (McAllister et al, 2003) . Thus, PKCe may selectively regulate WIN55,212-2 binding by phosphorylating residues on CB1 that alter the structure of such a domain.
Although Ser 317 on CB1 was previously identified as a PKC phosphorylation site, our results indicate that PKCe does not phosphorylate this residue. It is possible that PKCe regulates receptor affinity for WIN55,212-2 by phosphorylating other residues on the receptor. It is also possible that PKCe acts by phosphorylating and regulating the function of a different protein that is involved in CB1 receptor signaling. For example, different CB1 agonists initiate differential post-endocytotic sorting through the G-protein-associated sorting protein, which targets the receptor for recycling to the membrane or for degradation (Martini et al, 2007) . PKCe might regulate receptor sorting and recycling, thereby altering WIN55,212-2-stimulated CB1 signaling and its influence on behavior. Future analyses of PKCe-mediated phosphorylation of the CB1 receptor and its associated signaling proteins should reveal the sites at which PKCe acts.
The studies we present here provide the first evidence for modulation of brain CB1 receptor signaling by a specific member of the PKC family. PKCe À/À mice show enhanced responses to morphine (Newton et al, 2007) , and to ethanol and other drugs that are positive allosteric modulators of GABA A receptors (Hodge et al, 1999) . They also show increased GABA release in the central amygdala (Bajo et al, 2008) . The endogenous cannabinoid system exhibits cross talk with endogenous opioid systems (Robledo et al, 2008) and inhibition of GABA release is one of the downstream effects of cannabinoid signaling (Lovinger, 2008) . We do not know if effects of PKCe on opioid or GABAergic systems contribute to the cannabinoid phenotypes we have observed in this study. However, given the specificity of the phenotypes we observed for WIN55,212-2 and their inhibition by SR141716A, we believe that they are related to direct effects of PKCe on CB1 receptor signaling.
Abnormal function of the endogenous cannabinoid system has been implicated in many pathologies, including pain, affective and neurodegenerative disorders, inflammation, obesity and metabolic dysfunction (Di Marzo, 2008) . The development of CB1 agonists to treat these disorders has been limited by psychoactive side effects and the high degree of tolerance these compounds produce (De Vry et al, 2004; Gonzalez et al, 2005; Martin et al, 2004; Rubino et al, 2005) . Our finding that the effect of PKCe is selective for WIN55,212-2 is intriguing because it indicates that responses to specific CB1 agonists can be differentially regulated. Thus, it may be possible to alter affinity and tolerance to individual CB1 receptor agonists without affecting the action of other ligands, thereby providing a unique therapeutic strategy that could reduce side effects and the development of drug tolerance.
